Cagrilintide Peptide

Long-acting amylin analog acylated peptide. Studied for its interaction with amylin receptors and metabolic signaling pathways in preclinical models.

$85.00

Quick Facts

SKUACR-CAGRI
CAS Number2375228-45-4
Molecular Weight4004.6 g/mol
SequenceModified amylin analog
Purity≥97%
Physical FormLyophilized Powder
StorageStore at -20°C.

What is Cagrilintide?

Cagrilintide is a long-acting acylated amylin analog designed for extended-duration receptor activation. It is structurally derived from human amylin with key amino acid substitutions to prevent aggregation (the native amylin tendency to form amyloid fibrils) plus a C18 fatty diacid conjugation via a glutamic acid-containing linker for albumin binding. Cagrilintide binds with high affinity to amylin receptors (AMY1, AMY2, AMY3) — heteromeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs). Published research has investigated its pharmacokinetic profile enabling once-weekly dosing. For laboratory research use only.

Frequently Asked Questions

What is Cagrilintide?

Cagrilintide is a long-acting amylin analog with amino acid substitutions preventing aggregation and C18 fatty acid acylation for albumin binding. It activates AMY1-3 receptors (CTR+RAMP heterodimers). For research use only.

For laboratory and research use only. Not intended for human or animal consumption. All product information is derived from published preclinical research and does not constitute medical advice or claims.